Ionis Pharmaceuticals, Inc. (IONS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Core Viewpoint - Ionis has made significant progress over the past few years, positioning itself for substantial growth and value creation for stakeholders in the coming years [2]. Group 1: Company Evolution - Six years ago, Ionis transitioned from an R&D organization to a fully integrated commercial-stage biotechnology company [3]. - The company aims to drive substantial accelerating growth and value for all stakeholders [2]. Group 2: Leadership and Vision - Brett Monia has been the CEO of Ionis for nearly seven years and emphasizes the remarkable progress made during this time [2]. - The focus is on leveraging the momentum built over the last few years to achieve greater success [2].